Paris and Toulouse, France, December 4, 2017 – GamaMabs Pharma, a biotechnology company developing optimized therapeutic antibodies targeting AMHR2 for the treatment of cancer, today announces that two peer-reviewed articles have been published in the prestigious journal, Oncotarget, elaborating on the anti-tumor activity of GamaMabs’ lead compound GM102/3C23K for ovarian cancer. The studies were performed by GamaMabs’ partners, including the Institut de Recherche en Cancérologie de Montpellier, Inserm, Institut Curie and the Institut Gustave Roussy.
GM102/3C23K is a first-in-class monoclonal antibody (mAb) targeting the anti-Müllerian human receptor II (AMHR2/MISR2) which is expressed in a large proportion of gynecological cancers. Having a high affinity towards AMHR2, GM102 displays tumor cell killing properties through the enhanced activation of immune system cells, thanks to its EMABling® glyco-engineering technology. Based on the studies’ positive results a phase Ia/Ib trial with GM102 was launched in July 2016, with initial results expected early 2018.
Both published articles drew favorable conclusions regarding GamaMabs’ GM102/3C23K candidate in pre-clinical models, describing how the compound displays an original antitumor mode of action through the activation of tumor-associated macrophages, which predominantly infiltrate the ovarian cancers. Interestingly, it has been shown that activation of those macrophages by GM102/3C23K triggers high tumor cell killing by phagocytosis followed by unlocking adaptive immune system resulting in anti-tumoral T cell proliferation.
The articles are available at:
- P Estupina et al – The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells (https://doi.org/10.18632/oncotarget.15715)
- H Bougherara et al – The humanized anti-human AMHRII mAb 3C23K exerts an anti-tumor activity against human ovarian cancer through tumor-associated macrophages (https://doi.org/10.18632/oncotarget.21556)
“We are absolutely delighted by the conclusions of the two articles, confirming the potential of our mAb,” said Jean-François Prost, VP R&D at GamaMabs. “Following the positive articles published in such a prestigious journal, we are looking forward to sharing the first results of our ongoing in-man Phase Ia/Ib study.”
Ovarian cancer is the fifth most frequent cause of cancer death in women, with almost 60,000 deaths every year in Europe and the United States. (Source: Globocan 2012/WHO)
About GamaMabs Pharma
GamaMabs Pharma, a French immuno-oncology biotechnology company, is a leader in the development of optimized antibodies targeting AMHR2 for the treatment of cancer. Gamamabs’ first-in-class proprietary therapeutic monoclonal antibodies promise to have a broad commercial potential in cancer. GamaMabs Pharma’s lead project is the first-inclass monoclonal antibody (mAb) GM102. This antibody, which targets the anti-Müllerian human receptor II (AMHR2/MISR2), entered a first clinical trial in gynecological cancers in H1 2016. Initial results are expected early 2018. The company develops low-fucose EMABling® antibodies (license granted by LFB) with increased tumor cell killing properties through a breakthrough activation of immune system cells. GamaMabs also has a licensing agreement with MedImmune (USA) to develop an Antibody Drug Conjugate targeting cancer.
Media and analyst contacts
Andrew Lloyd & Associates
Agnes Stephens – Sandra Régnavaque
US: + 1 617 202 4491